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Purpose: We report a retrospective comparison between bi-dimensional RANO criteria and manual 
volumetric segmentation (MVS) in pediatric low grade gliomas. 
Methods: MRI FLAIR or T1 post contrast images were used for assessment of tumor response. 70 
patients were included in this single center study, for each patient two scans were assessed (“time 0” 
and “end of therapy”) and response to therapy was evaluated for both methods. Inter-reader variability 
and average time for volumetric assessment were also calculated.   
Results: 14 (20%) of the 70 patients had discordant results in terms of response assessment between 
the bi-dimensional measurements and MVS. All volumetric response assessments were in keeping 
with the subjective analysis of tumor (radiology report).  Of the 14 patients, 6 had stable disease (SD) 
on MVS and progressive disease (PD) on 2D assessment, 5 patients had SD on MVS and partial 
response (PR) on 2D assessment, 2 patients had PD on MVS and SD on 2D assessment, and 1 patient 
had PR on MVS and SD on 2D analysis. The number of discordant results rises to 21(30%) if minor 
response is integrated in the response assessment.  MVS was relatively fast and showed high inter-
reader concordance. 
Conclusion: Our analysis shows that therapeutic response classification may change in a significant 
number of children by performing a volumetric tumor assessment. Furthermore MVS is not 
particularly time consuming and has very good inter-reader concordance. 
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Pediatric low grade gliomas (pLGGs) are a heterogeneous category of neoplasms, consisting most 
commonly of pilocytic astrocytomas with a favorable 5-year survival rate, but potential for 
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recurrence, particularly in those incompletely resected [1, 2].  Although some pLGGs in 
accessible locations, such as the cerebellum, may be surgically cured, a large number of children 
will require adjuvant treatment.  
Over the last decades, chemotherapy has been increasingly used in the management of unresectable 
and/or progressive pLGGs, particularly in young children [3].  It has therefore become essential to 
titrate adjuvant therapies carefully to tumor response. Together with the patient’s clinical condition, 
imaging assessment forms the principal criterion by which pLGGs treatment efficacy is measured, 
whereby one of the major challenges is response quantification. Currently there is no widely validated 
method for pediatric brain tumor response assessment [4].  
 
The Macdonald criteria were first published in 1990 as guidelines for response assessments in adult 
supratentorial malignant gliomas, using the product of perpendicular measurements of enhancing 
tumor on axial post contrast images as a measure of tumor burden [5]. To incorporate non-enhancing 
tumor changes into the response assessment, and to address the problem of ‘pseudoprogression’, the 
RANO criteria were subsequently published in 2010 [6]. Despite some gain in assessment accuracy 
compared to previous methods, there are major limitations to the RANO criteria [7] and there is 
neither evidence nor consensus for the usefulness of these criteria in pLGGs. 
First of all enhancement of pLGGs is variable, heterogeneous and not representative of the tumor 
grade [8]. Additionally, there is no clear consensus that an objective response translates to 
improvements in progression-free survival [4], with some authors reporting good correlation 
between response and progression-free survival [9], and others not [10]. Pediatric brain tumors as 
a whole, and pLGGs in particular, differ significantly in prognosis and clinical course compared 
to their adult counterparts. The extrapolation of parameters of assessment for adult malignant 
gliomas has not been validated in the pediatric setting and it is probably suboptimal [11].   
 pLGGs are non-spherical and often have complex, mixed solid and cystic components.   Some 
irregularly shaped neoplasms such as visual pathway and hypothalamic gliomas may not be 
amenable to surgery but have a significant risk of progression.  In view of this, accurate imaging 
assessment in this group of patients is particularly important and this is why RANO assessment 
criteria for pLGGs have included minor response criteria to include tumors which show a 25-49% 
reduction in the area of non-enhancing lesion on T2/FLAIR [12]. 
Several studies have evaluated the role of one dimensional, two dimensional and volumetric 
assessment of size in brain tumors [13] [14]. These studies have largely focused on adult cohorts 
of patients, and include two pediatric comparative studies: the first by Warren et al, of One-, Two- 
and Three-dimensional measurements of childhood high grade brain tumors [15], and the second 
by Kilday et al on a small cohort (n=8) of pLGGs [16].  
The aim of this study was to perform a comparison between bi-dimensional measurements of 
tumor diameter based on the RANO method and manual volumetric segmentations (MVS) for 
pLGGs to determine response assessment. Furthermore we evaluated the clinical feasibility of 




Patients with LGG treated with weekly vinblastine at Sickkids (SK) hospital were included in this 
study. Some of the patients were from a phase II Canadian trial [17], the rest were treated as SK 
policies. Patients were included in the study if there was consensus between the two 
neuroradiologists (SL and FD’A, with respectively 25 and 3 years of experiences as pediatric 
neuroradiologist) that there was evidence of clearly measurable disease. Six patients with 
neurofibromatosis type 1 (NF1) were excluded since clear distinction between tumor and NF1-




All patients underwent MR imaging assessment at several time points (weeks 26, 39, 52, and 70).  
For each patient, 2 scans were analyzed: time point ‘zero’ is defined as the baseline scan (within 4 
weeks prior to the initiation of vinblastine), and follow up examination at the end of therapy 
(average 522 days).  Each subject was assigned to one of the categories “progressive disease 
(PD)”, “stable disease (SD)” or “tumor partial response (PR)” using data available in literature for 
each the 2D and volumetric assessment. Patients were considered eligible for analysis if their 
tumor measured at least 10 x 10 mm in maximum perpendicular diameter (definition of 
measurable lesion according to RANO criteria) and if the tumor could be visualized on a 
minimum of 4 consecutive slices. Tumors within the spinal cord, and patients with evidence of 
metastatic disease were excluded from the analysis.  
Image acquisition  
The MR images used for tumor assessment were FLAIR images, with the exception of those 
patients, in whom complete enhancement was present on the T1 post contrast sequences on both 
the scans. All images were acquired on either 1.5 Tesla or 3 Tesla Achieva scanners (Philips, The 
Netherlands) using a body coil for transmission and an 8-channel head coil for signal reception. 
The standard brain protocol consisted of: coronal T2WI (weighted images) (repetition time 
[TR]/echo time [TE]: 4811/ 120 ms; slice/gap: 5/1 mm; field of view [FOV]: 220 x 194 x 119 
mm; acquisition matrix: 400 x 289), axial FLAIR (TR/TE: 7000/ 140 ms; slice/gap: 5/1 mm; 
FOV: 220 x 181 x 119 mm; acquisition matrix: 292 x 222), axial diffusion weighted images 
(DWI) (TR/TE: 4799/ 70 ms; slice/gap: 5/0 mm; FOV: 150 x 198 x 150 mm; acquisition matrix: 
100 x 132), pre and post gadolinium axial 3D T1 turbo field echo with reformats in sagittal and 
coronal planes (TR/TE: 9.9/ 4.6 ms; voxel size 1 x 1 x 0.5 mm; FOV: 220 x 220 x 162 mm; 
acquisition matrix: 220 x 220).  
 
 DATA ANALYSIS. 
The margins of tumor and ideal sequences to identify the tumor margins, were established by 
consensus between the two neuroradiologists.  The majority of tumors showed variable 
enhancement, and delineation of tumor borders was best achieved in T2 FLAIR in 72% of 
patients.  However for completely enhancing tumors, for example chiasmatic optic pathway 
gliomas, the T1 post contrast sequences achieved higher resolution than flair and so calculations 
were based on these sequences.  For 2D analysis of tumor burden a measurement in millimeters 
was taken of the maximal tumor diameter on a single axial FLAIR (or axial T1 post contrast 
section if applicable). The product of the 2 diameters was calculated to form the tumor bi-
dimensional measurement [14, 18], with the same sequence for each patient being used for MVS. 
The decision if to use the T1 post contrast sequences was based on the opinion of the radiologist, 
depending on whether the enhancing component was judged to represent the entire tumor burden.   
MVS was undertaken by two pediatric neuroradiologists for all lesions (FD’A, FD). The tumor 
outline was delineated on axial images manually for each MR image showing the lesion. The volume 
was then calculated using the ‘region of interest (ROI) volume calculate’ plugin of the Osirix DICOM 
viewer (Osirix MD v.7.0.3, FDA cleared K101342, Pixmeo SARL, Switzerland), with intergap 
correction for FLAIR images [15] (Figure 1).  Table 1 shows response criteria for both 2D and 
volumetric assessments as described in literature [18].  Minor response is quoted as a 25 -49% 
decrease in the product of the perpendicular diameters on 2D measurements. For volumetric 
response criteria, progressive disease was defined as ≥40% increasing in 
calculated volume [18, 19] .  This assumption of spherical volume presumes equal growth of 
tumor in each direction.   Because RANO has extrapolated dimensions on the basis of a spherical 
shape of tumor, we further extrapolated this formula to include volumetric dimensions to facilitate 
comparison between the two methods.  Other geometric models for tumor volume include the 
ellipsoid, cylinder and rectangular formulas.  The ellipsoid model defines volume as 1/6 π LWH, 
where L,W,H represent diameters in the three axes of the tumor (length, width and height) [20],  
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while the rectangular formula defines the product of LWH.  The formula for the Cylinder model is  
V= π (W/2)2L.  Schmidt et al assess that the ellipsoid geometric model most closely approximates 
tumor volume, however both spherical and ellipsoid calculations showed significant variance in this 
comparison and correlations were poor, R=0.62 and 0.531 for ellipsoid and spherical models 
respectively [21].   A volumetric minor response criteria can be extrapolated from orthogonal 
diameter measurement using the formula from V = 4/3πr3 to include tumors with a 35-64% decrease 
in volume.  We have therefore further sub-categorized patients to include minor response.  It is 
important to note that the cut-off values for volumetric assessment represent a mathematical 
extrapolation from the linear values; in fact there are no prospective clinical studies available 
suggesting specific values for therapy response using volumetrics in pediatric brain tumors [18].   
All baseline and follow up MRI studies were reviewed by a certified pediatric neuro-radiologist 
(SL) to determine, if the volumetric assessment was consistent with the subjective interpretation 
of the changes in tumor size. The inter-reader variability in volumetric assessment was calculated 
on a sample of 12 baseline scans from the same study cohort using intraclass correlation 





A total of 70 patients, aged 0.56 to 16.75 years with a diagnosis of pLGGs were included in the 
study.  37 patients were male. 55 patients had a histologically proven diagnosis of pLGGs.  15 
patients did not undergo biopsy, however 14 of these had radiological appearances of an optic 
pathway glioma (OPG), of whom 9 had a history of NF1.  1 further patient with NF1 and a 
 hypothalamic tumor did not undergo biopsy.  13 of the 70 patients had a pre-existing diagnosis of 
NF1. Patient demographics are listed in table 2.   
Response assessments: 
The results in terms of difference in tumor size (%) between time zero and end-of-therapy follow-
up are summarized in table 3.  The median interval between studies is 522 days. On average, it 
took 10-15 minutes to complete MVS per patient / per scan. This did not include the time taken to 
export data and only included ROI drawing and software calculation of volume.  ROI drawing 
time ranged between 5.5-10 minutes and 7.3 to 14.9 minutes for Reader 1 (FD’A), and reader 2 
(FD) respectively.  Time taken to reach consensus on superior sequences for defining margins of 
the tumor is not included. 
14 (20%) of the 70 patients showed discordant results between 2D and MVS.  Of these, 6 patients 
had SD on MVS with 2D assessment categorizing the response as PD.  5 patients had SD on MVS 
with partial response (PR) identified on 2D assessment. 2 patients had PD on MVS, but SD was 
observed on 2D assessment. 1 patient had PR on MVS, but SD reported on 2D assessment. Of the 
6 patients who had SD on volumetric analysis, but PD on 2D assessment, 2 were pLGGs NOS, 
and 2 were pilocytic OPGs. The other 2 patients had tumors located in the thalamus and posterior 
fossa. Of the 5 patients with SD on MVS and PR on 2D, 4 patients had a diagnosis of OPG. 8 of 
the 14 discordant patients had OPG, i.e. 22% of all OPG patients studied.   
In 56 of 70 patients, the volumetric and 2D tumor assessments were deemed to be concordant in 
terms of the response assessment. Of these 56, 5 were concordant but with more than 50% 
difference in the measurement of disease response observed between the two methods. All of 
these 5 patients had PD, and for these patients the volumetric measurements showed a greater 
degree of progression compared to the bi-dimensional measurement. Of the remaining 51 patients 
with concordant measurements by both methods, 39 had SD, 7 patients had PD and 5 patients had 
PR.   
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When minor response (MR) is integrated to the analysis, 3 of the discordant patients with SD on 
MVS and PR in 2D assessment become MR in volumetric assessment.  1 discordant patient with 
PR on MVS and SD on 2D assessment became MR in 2D.  Furthermore, when integrating MR 
into the analysis of the previously 56 concordant patients, 6 patients change from SD to MR in 
both MVS and 2D assessment.  A further 4 patients remain in SD on MVS but move to MR in 2D 
assessment. 3 patients move to MR on MVS but remain in SD on 2D assessment. Integrating MR 
brings the total discordant patient total to 21 (30%) of patient cohort.   
There was a very good inter-reader variability for MSV on a sample of 12 patients (ICC=0.9, 




Accurate response assessment is critical to determine the impact of therapies. This is the largest study 
in children with pLGGs performing a direct comparison of bi-dimensional and volumetric tumor 
measurements. In our cohort, 20% of patients had discordant response assessments between the 2 
methods. For these patients the therapeutic response classification may change by performing a 
volumetric tumor assessment (allowing for the mathematical extrapolation of the cut-off values). This 
becomes significant when considering that radiological response is used as a primary endpoint in 
many pLGGs trials.  Glioma measurements can be challenging due to lack of a distinct tumor border, 
irregular lesion shape, variation in acquisition technique and head placement in the scanner [22, 23]. 
For pLGGs, the assessment of tumor burden according to the RANO criteria can be complicated by 
lack of gadolinium enhancement. Even in those pLGGs, in which contrast uptake is present, the 
enhancement pattern is often patchy and variable over time. In the majority of our patients, poorly 
 enhancing neoplasms were present, which is significantly different from the adult glioblastomas 
(GBM) patient group in whom the bi-dimensional measurement criteria were devised [6].  
The Macdonald criteria defined “size” as the largest cross-sectional area of the enhancing tumor [5], 
which is not a description suitable for most pLGGs. RANO criteria further built on this definition by 
including the evaluation of T2/FLAIR WI, in addition to clinical symptoms and the use of 
corticosteroids, but they are again based on different neoplasms and age group [6].  On imaging, 
pLGGs often do not exhibit surrounding edema and are best visualized on FLAIR and T2WI MRI 
sequences [12].  In view of the variability in contrast uptake and possible underestimation of the 
tumor size, 72% of children in this study underwent assessment of tumor burden using FLAIR 
images. Furthermore pLGGs differ considerably from adult counterpart in terms of molecular 
landscape and malignant transformation rate, which rarely occurs in the pediatric population [24, 25].   
For both RANO and Macdonald analyses, the radiologist decides the slice that should correspond to 
the largest appearing cross-section image of the tumor, this approach can be problematic for lesions 
that are non-spherical because structural heterogeneity and irregular borders can make it difficult to 
decide on the representative slice. In addition slight variations on serial imaging (e.g. with a slightly 
different image plane, head placement etc.) might impact reproducibility of measurements in irregular 
lesions [4, 23] [26]. In GBM good correlation between volumetric and bi-dimensional measurements 
was found [13],  this may be due, at least in part, to the fact that GBM grow very rapidly [27] and, 
therefore, small measuring errors would still produce the same result in terms of response criteria.  
The subjective visual analysis of the tumor response was consistent with the volumetric 
measurements in all cases, including in those cases, in which the radiological reports were discordant 
with 2D measurements. This was probably due to the irregular shape of the tumors, which may have 
limited the 2D assessment accuracy based on one slice only (Figure 2). While one may argue that the 
volumetric assessment is only as good as judgement of a trained radiologist, clinical trials require the 
objectively reproducible data for analysis, and therefore a consistent method of assessment of tumor 
size is necessary. 
The manual segmentation method used in our study is not significantly time consuming therefore 
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encouraging its integration into the clinical workflow. Additionally this method has shown excellent 
inter-rater reproducibility in a test sample of 12 patients.  
 
Most automatic and semi-automatic algorithms to date, have only reliably been shown to work in 
gadolinium enhancing lesions such as GBM [14].  In a study by Akkus et al. (2015) of semi-
automated segmentation of pLGGs on MRI T1 post-contrast and T2 WI, the intra-operator variability 
was lower than intra-expert variability and inter-operator variability much smaller than inter-expert 
variability [28]. While this is encouraging for establishing a standardized method of semi-automated 
analysis tumor volume in future, such methods need specific software, time for the operator to check 
the segmentation results and may be more useful for very complex and extensive lesions such as 
plexiform neurofibromas than relatively small pLGG [29]. In a further study by Porz et al, semi-
automated analysis of tumor volume was shown to be comparable to a full automated method of 
assessment [30], however, in this study all tumors were high grade enhancing masses. The lack or 
heterogeneity of enhancement typical of pLGGs and their relatively limited extension would likely 
hamper such an automated volumetric assessment and favor manual volumetric methods.   
In our cohort, 20% of patients had discordant response assessments between the 2 methods. For 
these patients the therapeutic response classification may change by performing a volumetric 
tumor assessment (allowing for the mathematical extrapolation of the cut-off values). This 
becomes significant when considering that radiological response is used as a primary endpoint in 
many pLGGs trials.  In the context of OPGs this may be of particular interest in view of the need 
to detect early tumor progression for patients whose functional vision is at risk. We would suggest 
volumetric assessment in pLGGs may be also valuable in clinical practice where a discrepancy 
exists between 2D assessment and the subjective analysis by the expert radiologist. The relatively 
short time taken for the volumetric assessment using our method makes this strategy useful for 
clinical practice.  
 
 Study Limitations: 
There are number of limiting factors of this study. One possible drawback is the need of specific 
software and correspondent expertise required to undertake volumetric assessment.  This has been 
noted as a limiting factor in previous studies [14], even though our method is relatively simple to 
use in comparison with  semi-automatic volumetric assessment.  
Another aspect to be considered is the fact that for some patients we used FLAIR images while for 
others we used post contrast 3D T1 images. Although this makes the method not entirely 
consistent, when evaluating subjectively a mass, a radiologist in clinical practice critically uses the 
sequence where the lesion is better visualized, so it seems reasonable, in our opinion, to assess the 
volume using the same process.  The lack of clinical data is noted to be a limiting factor of the 
study.  The focus of this study however is to compare the methods of 2D and MVS assessment of 
tumor burden.  The cohort of patients is part of a larger cohort of pLGG patients, whose 
assessment of response has not used volumetric data prospectively.   
 A further limiting factor is the slice thickness/gap (particularly relevant in FLAIR images); 
however the same limitations would influence the linear measurements and the software corrects 
for slice thickness/gap, with reduction of possible inaccuracies. Our method seems to be a good 
compromise between time and accuracy of measurement in the context of non-enhancing tumors 
since, at the moment, the use of automatic segmentation is not reliable [31]. Finally, as explained 
in the “data analysis” section, to use cut-off for volumetrics response based on a spherical 
mathematical extrapolation of linear measurements is suboptimal; however there are no 
prospective studies establishing cut-off values for LGG and this limiting factor stressed the 





Assessment according to RANO criteria is not reliable for complex shaped lesions such as pLGG; 
manual volumetric segmentation using Osirix software appears to be a feasible and more accurate 
method to quantify changes in tumor bulk on serial imaging.  Furthermore in a significant 
proportion of our patients with pLGGs, volumetric segmentation results may differ substantially 
from bi-dimensional measurements, and may have a clinical impact in management of the patients 
and in evaluation of tumor response in clinical trials. 
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Figure 1: Examples of ROI delineation for volume calculation on FLAIR axial images (A) and linear 
2D measurements on the same slice (B). 3D volume rendering of the tumor has been obtained using 
Osirix compute volume plugin with intergap correction (C) and shows the irregular structure of the 
tumor which makes inadequate the assessment using linear measurements only.  
Figure 2: The tumor in the slice 1 (used for 2D assessment) is stable in baseline and follow-up scans; 
however on follow up the mass appears to be less bulky in an upper slices (slice 2). The volumetric 
assessment confirmed the reduction in size (i.e. partial response) that was not appreciable using linear 
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Table 1: Response criteria for both 2D and volumetric assessments (see also Henson et al. AJNR 





CR Complete disappearance of the 
lesion on T2 or FLAIR imaging 
(if enhancement present, it must 
have resolved) 
Complete disappearance of the lesion 
PR ≥50% decrease in product of 2 
perpendicular diameters 
≥65% decrease in volume 
SD All others All others 
PD ≥25% increase in product of 
perpendicular diameters 
≥40% increase in volume. 
CR indicates complete response; PR partial response, SD stable disease, PD, progressive disease.  
Percentage changes are measured from baseline.  Product of perpendicular diameter in 2D 
assessment is measured on the section with the largest tumor area. 
 
Table 1 Click here to download Table Table 1 modified second
revision.docx
Table 2:  Patient Demographics 
Patient 
No: 






Histopathological diagnosis (if known) 
1 F No 16.75 Optic Pathway Pilocytic Astrocytoma 
2 M Yes 16.42 Optic Pathway No biopsy 
3 M Yes 9.16 Optic Pathway Low Grade Glioma NOS 
4 M No 12.58 Optic Pathway Pilocytic Astrocytoma 
5 F Yes 2.15 Optic Pathway  No biopsy 
6 
M No 7.88 
Hypothalamic/ 
Other Pilocytic Astrocytoma 
7 F Yes 10.84 Optic Pathway  No biopsy 
8 F No 12.16 Optic Pathway Pilocytic Astrocytoma 
9 M No 8.72 Optic Pathway  No biopsy 
10 M No 2.71 Optic Pathway Low Grade Glioma NOS 
11 




12 F No 5.01 Posterior Fossa Ganglioglioma 
13 M No 6.80 Optic Pathway Ganglioglioma 
14 M No 8.81 Optic Pathway Pilocytic Astrocytoma 
15 
F No 8.39 
Hypothalamic/ 
Other Pilocytic Astrocytoma 
16 
F No 6.75 
Hypothalamic/ 
Other, Other Pilomyxoid Astrocytoma 
17 F No 13.01 Thalamus Low Grade Glioma NOS 
18 
M No 16.53 
Hypothalamic/ 
Other Low Grade Glioma NOS 
19 
F No 8.25 
Hypothalamic/ 
Other Low Grade Glioma NOS 
20 F Yes 5.94 Optic Pathway  No biopsy 
21 M No 12.08 Posterior Fossa Pilocytic Astrocytoma 
22 F Yes 2.18 Optic Pathway  No biopsy 
23 F No 2.27 Optic Pathway  No biopsy 
24 M No 6.39 Brainstem Ganglioglioma 
25 M No 1.53 Brainstem Low Grade Glioma NOS 
26 F No 5.57 Brainstem Pilocytic Astrocytoma 
27 
M No 1.00 
Hypothalamic/ 
Other Pilomyxoid Astrocytoma 
28 F No 6.54 Brainstem Pilocytic Astrocytoma 
29 F No 0.57 Optic Pathway  No biopsy 
30 M No 6.22 Posterior Fossa Pilocytic Astrocytoma 
31 F No 14.48 Brainstem Pilocytic Astrocytoma 
32 F No 4.54 Posterior Fossa Pilomyxoid Astrocytoma 
33 
M No 11.24 
Hypothalamic/ 
Other Pilocytic Astrocytoma 
34 M Yes 5.85 Optic Pathway  No biopsy 
35 F No 0.93 Optic Pathway Low Grade Glioma NOS 
36 F Yes 3.24 Optic Pathway  No biopsy 
37 M No 13.38 Brainstem Low Grade Glioma NOS 
38 M No 0.56 Optic Pathway Low Grade Glioma NOS 
39 M No 11.97 Optic Pathway Low Grade Glioma NOS 
40 M No 6.99 Optic Pathway Pilocytic Astrocytoma 
41 M No 5.48 Brainstem Ganglioglioma 
42 M No 2.63 Optic Pathway Pilocytic Astrocytoma 
43 F No 13.62 Optic Pathway Pilocytic Astrocytoma 
Table 2 Click here to download Table Table 2 pt demographics.docx 
44 M Yes 16.42 Optic Pathway  No biopsy 
45 F No 10.26 Thalamus Pilocytic Astrocytoma 
46 F No 2.09 Optic Pathway Low Grade Glioma NOS 
47 M No 4.19 Optic Pathway Pilocytic Astrocytoma 
48 F No 7.59 Optic Pathway Pilocytic Astrocytoma 
49 
M No 15.88 
Hypothalamic/ 
Other Low Grade Glioma NOS 
50 F No 12.01 Optic Pathway Low Grade Glioma NOS 
51 M No 1.42 Optic Pathway Pilocytic Astrocytoma 
52 F No 11.32 Optic Pathway Pilocytic Astrocytoma 
53 M No 15.16 Brainstem Pilocytic Astrocytoma 
54 M Yes 3.28 Optic Pathway Pilomyxoid Astrocytoma 
55 M No 9.68 Optic Pathway  No biopsy 
56 




57 F No 10.53 Thalamus Low Grade Glioma NOS 
58 M No 4.06 Brainstem Pilocytic Astrocytoma 
59 F No 5.66 Brainstem Pilocytic Astrocytoma 
60 M No 9.82 Thalamus Pilocytic Astrocytoma 
61 M Yes 2.73 Optic Pathway  No biopsy 
62 
M No 1.00 
Hypothalamic/ 
Other Pilomyxoid Astrocytoma 
63 M No 6.22 Posterior Fossa Pilocytic Astrocytoma 
64   No 14.48 Brainstem Pilocytic Astrocytoma 
65 F No 0.93 Optic Pathway Low Grade Glioma NOS 
66 
M No 5.88 
Hypothalamic/ 
Other Low Grade Glioma NOS 
67 F Yes 8.01 Optic Pathway Ganglioglioma 
68 M No 2.24 Brainstem Pilocytic Astrocytoma 
69 
F Yes 10.18 
Hypothalamic/ 
Other  No biopsy 
70 F No 3.87 Optic Pathway  No biopsy 
 



















diagnosis (if known) 
1 -56.37% -52.08% SD (MR) PR Optic Pathway Pilocytic Astrocytoma 
2 -12.33% -12.59% SD SD Optic Pathway   
3 18.76% 3.41% SD SD Optic Pathway Low Grade Glioma 
NOS 
4 -9% -17.43% SD SD Optic Pathway Pilocytic Astrocytoma 
5 -47.66% -20% SD (MR) SD Optic Pathway   
6 -65.30% -33.31% PR SD (MR) Midline, Other Pilocytic Astrocytoma 
7 -23.50% -9.00% SD SD Optic Pathway   
8 -20% -23.40% SD SD Optic Pathway Pilocytic Astrocytoma 
9 47.50% 5.30% PD SD Optic Pathway   
10 7.13% 14.32% SD SD Optic Pathway Low Grade Glioma 
NOS 
11 -48.84% -27.67% SD (MR) SD (MR) Midline, Other Pilocytic Astrocytoma 
12 27.62% 38.33% SD PD Posterior 
Fossa 
Ganglioglioma 
13 52% -3.60% PD SD Optic Pathway Ganglioglioma 
14 -38.48% -26.76% SD (MR) SD (MR) Optic Pathway Pilocytic Astrocytoma 
15 28.56% 0.90% SD SD Midline, Other Pilocytic Astrocytoma 
16 -30.63% -10.90% SD SD Midline, Other Pilomyxoid 
Astrocytoma 
17 21.87% 22.89% SD SD Thalamus Low Grade Glioma 
NOS 
18 -26.13% -20.16% SD SD Midline, Other Low Grade Glioma 
NOS 
19 34.87% 33.06% SD PD Midline, Other Low Grade Glioma 
NOS 
20 -55.30% -61.25% SD (MR) PR Optic Pathway   
21 14.78% 18.81% SD SD Posterior 
Fossa 
Pilocytic Astrocytoma 
22 -40% -43.53% SD (MR) SD (MR) Optic Pathway   
23 153% 97.30% PD PD Optic Pathway   
24 30.50% 18.40% SD SD Brainstem Ganglioglioma 
25 3.70% -4% SD SD Brainstem Low Grade Glioma 
NOS 
26 78% 108.27% PD PD Brainstem Pilocytic Astrocytoma 
27 -41.31% -35.43% SD (MR) SD (MR) Midline, Other Pilomyxoid 
Astrocytoma 
28 -12.50% 2.10% SD SD Brainstem Pilocytic Astrocytoma 
29 -19% -55% SD PR Optic Pathway   
30 -38.86% -16.65% SD (MR) SD Posterior 
Fossa 
Pilocytic Astrocytoma 
31 -49.40% -41.40% SD (MR) SD (MR) Brainstem Pilocytic Astrocytoma 




33 113% 61.53% PD PD Midline, Other Pilocytic Astrocytoma 
34 -24% -13.00% SD SD Optic Pathway   
35 202.08% 100.86% PD PD Optic Pathway Low Grade Glioma 
NOS 
36 -43.12% -9.01% SD (MR) SD Optic Pathway   
37 9.84% 9.03% SD SD Brainstem Low Grade Glioma 
NOS 
Table 3 Click here to download Table Table 3 volumetric analysis.docx 
38 72.69% 39.85% PD PD Optic Pathway Low Grade Glioma 
NOS 
39 -83.19% -77.52% PR PR Optic Pathway Low Grade Glioma 
NOS 
40 15.93% 6.90% SD SD Optic Pathway Pilocytic Astrocytoma 
41 3.80% -7.80% SD SD Brainstem Ganglioglioma 
42 -3.40% -30.10% SD SD (MR) Optic Pathway Pilocytic Astrocytoma 
43 -67.31% -52.31% PR PR Optic Pathway Pilocytic Astrocytoma 
44 -12.33% -12.59% SD SD Optic Pathway   
45 116.49% 76% PD PD Thalamus Pilocytic Astrocytoma 
46 -27.65% -46.85% SD SD (MR) Optic Pathway Low Grade Glioma 
NOS 
47 125.81% 99.06% PD PD Optic Pathway Pilocytic Astrocytoma 
48 4.60% -1.54% SD SD Optic Pathway Pilocytic Astrocytoma 
49 -84.68% -55.42% PR PR Midline, Other Low Grade Glioma 
NOS 
50 -7% -3.50% SD SD Optic Pathway Low Grade Glioma 
NOS 
51 -67.30% -53.42% PR PR Optic Pathway Pilocytic Astrocytoma 
52 11.63% 41.37% SD PD Optic Pathway Pilocytic Astrocytoma 
53 -27.52% -19.72% SD SD Brainstem Pilocytic Astrocytoma 
54 3.54% -7.10% SD SD Optic Pathway Pilomyxoid 
Astrocytoma 
55 -43.20% -65.87% SD (MR) PR Optic Pathway   
56 131.62% 64% PD PD Midline, Other Pilomyxoid 
Astrocytoma 
57 -65.87% -50.40% PR PR Thalamus Low Grade Glioma 
NOS 
58 12.36% -55.55% SD PR Brainstem Pilocytic Astrocytoma 
59 48.43% 62.81% PD PD Brainstem Pilocytic Astrocytoma 
60 4.20% 78.90% SD PD Thalamus Pilocytic Astrocytoma 
61 12.63% 37.20% SD PD Optic Pathway   
62 10.98% 7.92 SD SD Midline, Other Pilomyxoid 
Astrocytoma 
63 -18.34% -30.48% SD SD (MR) Posterior 
Fossa 
Pilocytic Astrocytoma 
64 -47.55% -35.20% SD (MR) SD (MR) Brainstem Pilocytic Astrocytoma 
65 202.08% 100.86% PD PD Optic Pathway Low Grade Glioma 
NOS 
66 29.62% 30.75% SD PD Midline, Other Low Grade Glioma 
NOS 
67 -17.65% -40.41% SD SD (MR) Optic Pathway Ganglioglioma 
68 49.34% 45.34% PD PD Brainstem Pilocytic Astrocytoma 
69 58.78% 39.80% PD PD Midline, Other   
70 -26.19% -20.09% SD SD Optic Pathway   
Patients who had discordant results of the tumor response assessment are highlighted.  SD: stable 
disease; PD: progressive disease; PR: partial response; MR: minor response.  
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